Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Q&A: Disrupting DNA synthesis with Twist’s Emily Leproust

Synthetic biology, and particularly DNA synthesis, is transforming diagnosis and treatment of disease. Allie Nawrat talks to CEO and co-founder Dr Emily Leproust about how Twist’s novel approach has disrupted the DNA synthesis field and how the company plans to duplicate this and shake up drug discovery and development.


Go Top